Head-to-head · Value Score
CoreAge Rx vs NexLife
Two GLP-1 deals, scored on the same six factors. CoreAge Rx lands a Value Score of 93, NexLife a 72. Here's who gives you the honest lower price — and where each one bites back.
CoreAge Rx
#1 · Grade A+ · Best Value
Est. first month
$99/mo
Save ~89% vs brand-nameNexLife
#194 · Grade C · Watch List
Est. first month
From $139/mo (as low as $119/mo on a 12-month plan, compounded)
Save ~90% vs brand-nameFDA warning letter. The FDA issued Nexlife Inc. dba Nexlife a warning letter in June 2026. Check it on the FDA database.
Get this deal Full NexLife review →The verdict
CoreAge Rx takes it on Value Score, 93 to 72 — an est. $99/mo first month, with no teaser step-up baked in. NexLife isn't out of it: Someone comparing month-to-month rates who will read which figure carries the asterisk.
CoreAge Rx is also our overall #1 pick across the whole deals ranking — a flat, all-in price on both molecules in all 50 states. That's why it wins here on the score, not just this matchup.
Deal-by-deal
The numbers that decide it. Green ✓ marks the stronger side on each line.
| Deal | CoreAge Rx | NexLife |
|---|---|---|
| Value Score | 93 (A+) | 72 (C) |
| Est. first month | $99/mo | From $139/mo (as low as $119/mo on a 12-month plan, compounded) |
| Save vs brand-name | ~89% | ~90% |
| Semaglutide | $99/mo | From $139/mo (as low as $119/mo on a 12-month plan, compounded) |
| Tirzepatide | $149/mo | From $169/mo (compounded) |
| Both molecules | Yes | Yes |
| Pricing | Flat — no step-up | Watch |
| Coverage | All 50 states | Coverage not published |
Factor by factor
The six factors behind each Value Score. The orange bar marks the stronger side. See the methodology.
CoreAge Rx
The honest lowest price: both molecules at one flat, all-in monthly rate that never steps up after month one.
Why it's a deal
- Flat, all-in monthly price with no intro-rate step-ups after month one
- Both compounded semaglutide and tirzepatide on one account
- Available in all 50 states
- Straightforward, low-friction cancellation — no lock-in
The fine print
- Not the rock-bottom sticker — a couple of teaser tiers advertise lower month-one rates
- No FDA-approved brand-name option (compounded only)
- Does not yet publicly name its 503A/B pharmacy partner
NexLife
NexLife is a LegitScript-certified telehealth platform selling compounded semaglutide from $139 and tirzepatide from $169 a month, with a $119 rate available to anyone committing to twelve months.
Why it's a deal
- Publishes the month-to-month rate and the twelve-month rate separately rather than showing only the lower one
- The subscription is stated to include provider consultations, the treatment and on-demand medical support with no hidden fees
- All plans are FSA and HSA eligible, with free expedited delivery
- Same-day messaging with the clinical team rather than a ticket queue
The fine print
- The $119 figure that appears across the site needs a twelve-month commitment; the month-to-month rate is $139
- The states served are not publicly disclosed
- GLP-1s sit beside hormone-optimization and longevity lines rather than being the sole focus
- Compounded only — no FDA-approved brand-name route
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes a Value Score.
Neither one the right fit? Every program that outscores CoreAge Rx is ranked on the CoreAge Rx alternatives ranking, and the same list for the other side is on alternatives to NexLife.
More head-to-heads
Prices, states and verification reflect each program's public disclosures at last check; the Value Score is our editorial judgment per the methodology. “Save vs brand-name” compares the lowest disclosed monthly price against a ~$1,349/mo brand-name cash reference. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.